Aclaris Therapeutics, Inc. (ACRS)
USD 3.08
(-5.52%)
USD 3.08
(-5.52%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 110.52 Million USD | 25.78% |
| 2022 | 102.94 Million USD | 52.67% |
| 2021 | 67.43 Million USD | 29.03% |
| 2020 | 52.26 Million USD | -43.64% |
| 2019 | 92.72 Million USD | -33.12% |
| 2018 | 138.65 Million USD | 90.2% |
| 2017 | 72.89 Million USD | 50.1% |
| 2016 | 48.56 Million USD | 135.0% |
| 2015 | 20.66 Million USD | 142.2% |
| 2014 | 8.53 Million USD | 62.32% |
| 2013 | 5.25 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 14.18 Million USD | -59.3% |
| 2024 Q2 | 13.41 Million USD | -5.48% |
| 2023 Q4 | 34.86 Million USD | -12.87% |
| 2023 Q3 | 40.01 Million USD | 19.11% |
| 2023 Q2 | 33.59 Million USD | 7.06% |
| 2023 FY | 129.48 Million USD | 25.78% |
| 2023 Q1 | 31.37 Million USD | 11.19% |
| 2022 Q4 | 28.21 Million USD | -4.25% |
| 2022 Q2 | 24.85 Million USD | 21.8% |
| 2022 Q1 | 20.4 Million USD | -3.04% |
| 2022 FY | 102.94 Million USD | 52.67% |
| 2022 Q3 | 29.46 Million USD | 18.57% |
| 2021 FY | 67.43 Million USD | 29.03% |
| 2021 Q3 | 19.95 Million USD | 44.95% |
| 2021 Q4 | 21.04 Million USD | 5.46% |
| 2021 Q1 | 12.66 Million USD | -8.58% |
| 2021 Q2 | 13.76 Million USD | 8.7% |
| 2020 Q2 | 12.03 Million USD | -23.05% |
| 2020 FY | 52.26 Million USD | -43.64% |
| 2020 Q4 | 13.85 Million USD | 29.17% |
| 2020 Q1 | 15.64 Million USD | -9.83% |
| 2020 Q3 | 10.72 Million USD | -10.91% |
| 2019 Q2 | 34.44 Million USD | -13.01% |
| 2019 Q3 | 22.46 Million USD | -34.78% |
| 2019 FY | 92.72 Million USD | -33.12% |
| 2019 Q4 | 17.34 Million USD | -22.79% |
| 2019 Q1 | 39.59 Million USD | 1.02% |
| 2018 Q3 | 33.88 Million USD | 2.77% |
| 2018 FY | 138.65 Million USD | 90.2% |
| 2018 Q4 | 39.19 Million USD | 15.68% |
| 2018 Q2 | 32.97 Million USD | 6.03% |
| 2018 Q1 | 31.09 Million USD | 21.07% |
| 2017 Q2 | 15.29 Million USD | 18.29% |
| 2017 Q3 | 18.98 Million USD | 24.14% |
| 2017 Q4 | 25.68 Million USD | 35.29% |
| 2017 FY | 72.89 Million USD | 50.1% |
| 2017 Q1 | 12.93 Million USD | 11.21% |
| 2016 Q4 | 11.62 Million USD | 7.54% |
| 2016 Q3 | 10.81 Million USD | -16.76% |
| 2016 FY | 48.56 Million USD | 135.0% |
| 2016 Q1 | 13.13 Million USD | 173.62% |
| 2016 Q2 | 12.98 Million USD | -1.14% |
| 2015 Q3 | 10.64 Million USD | 309.86% |
| 2015 Q1 | 2.62 Million USD | 1.04% |
| 2015 Q4 | 4.8 Million USD | -54.87% |
| 2015 Q2 | 2.59 Million USD | -1.26% |
| 2015 FY | 20.66 Million USD | 142.2% |
| 2014 FY | 8.53 Million USD | 62.32% |
| 2014 Q3 | 2.66 Million USD | 62.86% |
| 2014 Q4 | 2.6 Million USD | -2.25% |
| 2014 Q2 | 1.63 Million USD | 0.0% |
| 2014 Q1 | 1.63 Million USD | 0.0% |
| 2013 FY | 5.25 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 25.819% |
| Prenetics Global Limited | 60.73 Million USD | -81.974% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -579.234% |
| CareDx, Inc | 277.76 Million USD | 60.21% |
| Exact Sciences Corporation | 2.06 Billion USD | 94.636% |
| Exagen Inc. | 52.29 Million USD | -111.357% |
| Inotiv, Inc. | 246.9 Million USD | 55.235% |
| Guardant Health, Inc. | 901.62 Million USD | 87.742% |
| Biodesix, Inc. | 77.41 Million USD | -42.762% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -2717.297% |
| Precipio, Inc. | 13.63 Million USD | -710.419% |
| iSpecimen Inc. | 16.27 Million USD | -579.015% |
| Natera, Inc. | 938.98 Million USD | 88.229% |
| Aspira Women's Health Inc. | 24.11 Million USD | -358.344% |
| Standard BioTools Inc. | 113.48 Million USD | 2.612% |
| 23andMe Holding Co. | 420.73 Million USD | 73.73% |
| Castle Biosciences, Inc. | 242.78 Million USD | 54.476% |
| Personalis, Inc. | 128.14 Million USD | 13.749% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -570.388% |
| OpGen, Inc. | 30.65 Million USD | -260.51% |
| T2 Biosystems, Inc. | 41.49 Million USD | -166.364% |
| Myriad Genetics, Inc. | 600.1 Million USD | 81.582% |
| ICON Public Limited Company | 755.64 Million USD | 85.373% |
| NeoGenomics, Inc. | 341.25 Million USD | 67.612% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -579.234% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 89.886% |
| RadNet, Inc. | 268.87 Million USD | 58.894% |
| MDxHealth SA | 71.25 Million USD | -55.11% |
| Psychemedics Corporation | 11.33 Million USD | -875.163% |
| Illumina, Inc. | 3.81 Billion USD | 97.101% |
| Check-Cap Ltd. | 19.28 Million USD | -473.054% |
| Twist Bioscience Corporation | 354.18 Million USD | 68.794% |
| DarioHealth Corp. | 62.17 Million USD | -77.77% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 35.706% |
| Sera Prognostics, Inc. | 39.91 Million USD | -176.887% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -950.544% |
| OPKO Health, Inc. | 574.68 Million USD | 80.768% |
| Medpace Holdings, Inc. | 187.68 Million USD | 41.11% |
| Neogen Corporation | 405.23 Million USD | 72.726% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -843.948% |
| Prenetics Global Limited | 60.73 Million USD | -81.974% |
| Mainz Biomed B.V. | 27.15 Million USD | -307.025% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -1161.004% |
| Trinity Biotech plc | 46.49 Million USD | -137.714% |
| Neuronetics, Inc. | 82.25 Million USD | -34.362% |
| Sotera Health Company | 300.46 Million USD | 63.215% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -1161.004% |